Q1 Earnings Estimate for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS) – Stock analysts at William Blair raised their Q1 2025 EPS estimates for shares of 908 Devices in a research report issued to clients and investors on Monday, March 10th. William Blair analyst M. Larew now expects that the company will post earnings per share of ($0.27) for the quarter, up from their previous forecast of ($0.37). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.54) EPS.

A number of other equities research analysts have also issued reports on MASS. Stephens reissued an “overweight” rating and issued a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, 908 Devices has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Trading Down 3.1 %

MASS opened at $4.32 on Thursday. The stock has a market capitalization of $150.44 million, a P/E ratio of -2.44 and a beta of 0.99. 908 Devices has a 12-month low of $1.81 and a 12-month high of $7.56. The stock has a 50-day moving average price of $2.65 and a 200-day moving average price of $2.92.

Institutional Investors Weigh In On 908 Devices

Large investors have recently added to or reduced their stakes in the stock. Drive Wealth Management LLC purchased a new position in 908 Devices in the 3rd quarter worth about $50,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in 908 Devices during the 3rd quarter worth $190,000. Charles Schwab Investment Management Inc. boosted its stake in 908 Devices by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after purchasing an additional 28,015 shares in the last quarter. 49 Wealth Management LLC grew its position in 908 Devices by 16.2% during the 3rd quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock worth $108,000 after purchasing an additional 4,343 shares during the period. Finally, Townsquare Capital LLC acquired a new position in shares of 908 Devices in the 3rd quarter valued at about $50,000. 88.06% of the stock is owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.